Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled $ ALIC^{4} $E trial in 15 European countries
Background Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries. Methods Direct and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers’ and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed. Results The healthcare payers’ expected ICERs of oseltamivir were €22,459 per QALY gained in adults/adolescents and €13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is €8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged €1–€35 per patient). Conclusion Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers’ perspective (if willingness-to-pay per QALY gained > €22,459) and cost-saving in adults/adolescents from a societal perspective..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
The European journal of health economics - 24(2022), 6 vom: 22. Sept., Seite 909-922 |
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Cost-utility analysis |
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s10198-022-01521-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144086001 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144086001 | ||
| 003 | DE-627 | ||
| 005 | 20240118093224.0 | ||
| 007 | tu | ||
| 008 | 240118s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10198-022-01521-2 |2 doi | |
| 035 | |a (DE-627)OLC2144086001 | ||
| 035 | |a (DE-He213)s10198-022-01521-2-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 330 |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.05$jGesundheitsökonomie |2 bkl | ||
| 084 | |a 44.10$jGesundheitswesen: Allgemeines |2 bkl | ||
| 100 | 1 | |a Li, Xiao |e verfasserin |0 (orcid)0000-0002-1918-1791 |4 aut | |
| 245 | 1 | 0 | |a Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled $ ALIC^{4} $E trial in 15 European countries |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Background Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries. Methods Direct and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers’ and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed. Results The healthcare payers’ expected ICERs of oseltamivir were €22,459 per QALY gained in adults/adolescents and €13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is €8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged €1–€35 per patient). Conclusion Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers’ perspective (if willingness-to-pay per QALY gained > €22,459) and cost-saving in adults/adolescents from a societal perspective. | ||
| 650 | 4 | |a Tamiflu | |
| 650 | 4 | |a Cost-utility analysis | |
| 650 | 4 | |a Europe | |
| 650 | 4 | |a Multi-country | |
| 650 | 4 | |a QALY | |
| 650 | 4 | |a ILI | |
| 650 | 4 | |a Direct cost | |
| 650 | 4 | |a Indirect cost | |
| 650 | 4 | |a Productivity losses | |
| 700 | 1 | |a Bilcke, Joke |0 (orcid)0000-0001-5720-5291 |4 aut | |
| 700 | 1 | |a van der Velden, Alike W. |0 (orcid)0000-0002-9443-2837 |4 aut | |
| 700 | 1 | |a Bruyndonckx, Robin |0 (orcid)0000-0002-4217-2869 |4 aut | |
| 700 | 1 | |a Coenen, Samuel |0 (orcid)0000-0002-1238-8052 |4 aut | |
| 700 | 1 | |a Bongard, Emily |0 (orcid)0000-0001-5957-6280 |4 aut | |
| 700 | 1 | |a de Paor, Muirrean |4 aut | |
| 700 | 1 | |a Chlabicz, Slawomir |0 (orcid)0000-0001-5022-4588 |4 aut | |
| 700 | 1 | |a Godycki-Cwirko, Maciek |4 aut | |
| 700 | 1 | |a Francis, Nick |0 (orcid)0000-0001-8939-7312 |4 aut | |
| 700 | 1 | |a Aabenhus, Rune |0 (orcid)0000-0001-9354-2236 |4 aut | |
| 700 | 1 | |a Bucher, Heiner C. |4 aut | |
| 700 | 1 | |a Colliers, Annelies |4 aut | |
| 700 | 1 | |a De Sutter, An |0 (orcid)0000-0002-2540-8307 |4 aut | |
| 700 | 1 | |a Garcia-Sangenis, Ana |0 (orcid)0000-0002-6689-6466 |4 aut | |
| 700 | 1 | |a Glinz, Dominik |0 (orcid)0000-0003-3509-8186 |4 aut | |
| 700 | 1 | |a Harbin, Nicolay J. |0 (orcid)0000-0002-3005-6908 |4 aut | |
| 700 | 1 | |a Kosiek, Katarzyna |4 aut | |
| 700 | 1 | |a Lindbæk, Morten |4 aut | |
| 700 | 1 | |a Lionis, Christos |0 (orcid)0000-0002-9324-2839 |4 aut | |
| 700 | 1 | |a Llor, Carl |0 (orcid)0000-0001-6644-717X |4 aut | |
| 700 | 1 | |a Mikó-Pauer, Réka |4 aut | |
| 700 | 1 | |a Radzeviciene Jurgute, Ruta |4 aut | |
| 700 | 1 | |a Seifert, Bohumil |0 (orcid)0000-0002-6881-8840 |4 aut | |
| 700 | 1 | |a Sundvall, Pär-Daniel |0 (orcid)0000-0001-9889-509X |4 aut | |
| 700 | 1 | |a Touboul Lundgren, Pia |4 aut | |
| 700 | 1 | |a Tsakountakis, Nikolaos |4 aut | |
| 700 | 1 | |a Verheij, Theo J. |4 aut | |
| 700 | 1 | |a Goossens, Herman |4 aut | |
| 700 | 1 | |a Butler, Christopher C. |4 aut | |
| 700 | 1 | |a Beutels, Philippe |0 (orcid)0000-0001-5034-3595 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European journal of health economics |d Springer Berlin Heidelberg, 2001 |g 24(2022), 6 vom: 22. Sept., Seite 909-922 |w (DE-627)328188557 |w (DE-600)2045253-6 |w (DE-576)09442246X |x 1618-7598 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:6 |g day:22 |g month:09 |g pages:909-922 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10198-022-01521-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-WIW | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_4277 | ||
| 912 | |a GBV_ILN_4310 | ||
| 936 | b | k | |a 44.05$jGesundheitsökonomie |q VZ |0 106409611 |0 (DE-625)106409611 |
| 936 | b | k | |a 44.10$jGesundheitswesen: Allgemeines |q VZ |0 106409530 |0 (DE-625)106409530 |
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 6 |b 22 |c 09 |h 909-922 | ||